Astrazeneca Pharma India gets CDSCO approval for Acalabrutinib tablets

Through this approval, Acalabrutinib tablets 100 mg in combination with venetoclax with or without obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) /small lymphocytic lymphoma (SLL).

This regulatory clearance paves the way for the commercial launch and availability of Calquence in the Indian market.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company?s standalone net profit declined 42.3% to Rs 31.55 crore despite 38.9% increase in net sales to Rs 615.57 crore in Q3 FY26 over Q3 FY25.

The counter advanced 1.45% to end at Rs 8,291.50 on Friday, 10 April 2026.